SRR1440308
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.406
- SPERMATOGENESIS+0.390
- KRAS_SIGNALING_DN+0.342
- MYOGENESIS+0.243
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.217
- COAGULATION+0.159
- FATTY_ACID_METABOLISM+0.147
- XENOBIOTIC_METABOLISM+0.136
- ESTROGEN_RESPONSE_LATE+0.119
- BILE_ACID_METABOLISM+0.081
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.490
- TNFA_SIGNALING_VIA_NFKB-0.454
- G2M_CHECKPOINT-0.436
- INTERFERON_GAMMA_RESPONSE-0.428
- E2F_TARGETS-0.406
- INTERFERON_ALPHA_RESPONSE-0.405
- PROTEIN_SECRETION-0.384
- MITOTIC_SPINDLE-0.375
- INFLAMMATORY_RESPONSE-0.368
- MTORC1_SIGNALING-0.352
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1445347 | GTEX | — | 0.955 |
| 2 | SRR1418923 | GTEX | — | 0.953 |
| 3 | SRR1468381 | GTEX | — | 0.949 |
| 4 | SRR1314767 | GTEX | — | 0.947 |
| 5 | SRR658247 | GTEX | — | 0.944 |
| 6 | SRR1366433 | GTEX | — | 0.940 |
| 7 | SRR817797 | GTEX | — | 0.934 |
| 8 | SRR1357434 | GTEX | — | 0.931 |
| 9 | SRR1410264 | GTEX | — | 0.931 |
| 10 | SRR1340907 | GTEX | — | 0.926 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.406 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.390 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.342 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.243 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.217 | Inavolisib | — uncovered |
| COAGULATION | 0.159 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.147 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.136 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.119 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.081 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.056 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.029 | Temsirolimus | — uncovered |